Abstract Although the technological change in medicine has been recognized widely as the major driver of rising healthcare costs, there is very little research that estimates this effect directly. This paper uses both a single-equation and a simultaneous equations approach to investigate empirically the interactive relationship between technological innovation and the growth of health expenditure in the context of the pharmaceutical market in Taiwan. Based on observing 182 therapeutic groups between 1997 and 2006, we find evidence to support the argument that technological innovation and health expenditure are determined simultaneously as technological innovation, and that the growth of health expenditure are endogenous rather than exogenous. Specifically, we find that therapeutic groups associated with higher pharmaceutical expenditure are likely to attract more new products to the market. Meanwhile, therapeutic groups with more new products are associated with higher pharmaceutical expenditures. An important implication of the paper is that cost containment policies will affect not only the growth of health expenditure, but also the progress of technological innovation in the health sector.
Introduction
Health expenditures measure a country's final consumption of health care goods and services plus capital investment in health care infrastructure. International comparison of health expenditures reveals two stylized facts. First, at a point in time, there is substantial variation in health expenditures between countries, not only in terms of health expenditures, but also as a share of GDP. Second, over time, a large number of countries that have been studied, irrespective of whether their health expenditure levels were initially high or low, experience a similar trend in health expenditure growth. In particular, the growth rate of health expenditures has constantly exceeded the growth rate of GDP.
These stylized facts provide an impetus for research on the causes of these increases. The bulk of the empirical evidence provides consistent findings on the determinants of personal health expenditures. National income (i.e., GDP per capita) is the most important determinant of the cross-sectional variation in health expenditures (see Gerdtham and Jönsson [9] ). While differences in income alone can explain most of the cross-sectional variation in health expenditure, growth in income cannot explain why health expenditures have risen so substantially over time. Other factors, such as population aging, increased coverage of health insurance, growth in the number of health professionals and hospital capacity, and lower productivity growth in the service sector than in other sectors of the countries' economies, may explain part of the story. However, Newhouse [19] explained that the above-mentioned factors, taken together, account for less than half of the long-run growth in health expenditure. Instead, Newhouse [19] argued that the major part of the increase in health expenditure stems from technological change in health care. Included in technological change are newly developed types of equipment and pharmaceuticals as well as new surgical technologies and the development and diffusion of such technological tools as renal dialysis.
This view is supported by empirical evidence and is also widely accepted by health economists [8, 21] . However, researchers have traditionally treated technological change in medicine as an exogenous factor, but technological change in medicine-like technological change in the economy as a whole-is, in fact, endogenous, or generated by factors within the healthcare system. 1 The purpose of this paper is to investigate empirically the determinants of technological change in medicine and its impact on healthcare costs. Specifically, we estimate a twoequation model that contains both technological innovation and health expenditure. We compare the empirical results from treating technological innovation as an endogenous variable as compared with treating it as an exogenous variable in the simultaneous equation model. As a substantial amount of technological progress in medicine has taken the form of pharmaceutical innovation in recent years, we use the pharmaceutical market as an example to test our hypothesis regarding exogeneity versus endogeneity. Specifically, we test the following two hypotheses: (1) therapeutic groups associated with higher pharmaceutical expenditure are likely to attract more entry of new products; and (2) therapeutic groups associated with greater pharmaceutical innovation tend to have higher levels of pharmaceutical expenditure.
The remainder of the paper is organized as follows. ''Previous research'' provides a review of the research that investigates the effects of technological change on the growth of health expenditure, and the determinants that affect the progress of technological change. ''Background'' briefly describes the features of the pharmaceutical market in Taiwan. ''Empirical framework'' provides an analytical framework to explain the interaction between the entry of new drugs and health care costs. ''Data and variables'' describes the data and methodology used in the empirical analysis. ''Empirical results'' presents and analyzes the empirical results, and ''Conclusion'' summarizes the findings and discusses some policy implications.
Previous research
Since the publication of the seminal papers of Kleiman [12] and Newhouse [20] , the determinants of health expenditure have been a major focus of research in the field of health economics. A considerable number of studies in this line highlight the role of income to explain cross-country variations and long-term growth in health expenditure [2] [3] [4] . However, little attention has been paid to testing the role of technological innovation in accounting for health expenditure growth. A plausible explanation for the paucity of such research is that searching for an appropriate proxy for technological change in medicine can be difficult.
Okunade and Murthy [21] overcame this difficulty by using total R&D spending and R&D spending specific to health care in the United States as proxies for health care technology. They found empirical evidence in support of Newhouse's [19] argument that technological change is a statistically significant long-term driver of rising health care expenditure.
Although research that directly estimates the effects of technological innovation on rising healthcare costs has been scarce, a growing body of research has focused on the effect of technological change in medicine on improvements in population health which, in turn, provides additional information on alternative measures of technological innovation in practice. Along this line of research, some studies have focused on technological change in medicine, in general, while others have focused on pharmaceutical innovation, in particular. For example, Papageorgious et al. [22] argued that the rest of the world may benefit from medical technological change occurring in countries at the frontier of medical technology. They measured the diffusion of technological change in medicine by medical imports as well as the diffusion in the forms of ideas, e.g., the number of foreign-trained medical students.
Other studies that have focused specifically on pharmaceutical innovation rely on three different types of proxies to measure technological change: (1) the cumulative number of drugs approved with new molecular entities; (2) newer drugs as a proportion of total prescriptions; and (3) the average vintage of drugs [13] [14] [15] . For example, Lichtenberg [15] used the first approach and emphasized that approval of new molecular entities represents the most important form of innovation. Using the cumulative number of new molecular entities available in the market by year, Lichtenberg [15] found a significantly positive relationship between his measure of pharmaceutical innovation and life expectancy in the United States and in a sample containing data from 52 countries.
These studies treat technological change as an exogenous variable, and hence do not address the issue of how technological change in medicine evolves over time. As noted by Smith et al. [23] , the rate of technological innovation does not expand independently of the historical context but is rather influenced by various factors, such as the size of the market, rising income and more generous insurance coverage. As a result, a growing body of research has attempted to explain the major drivers of technological innovation in health care.
In this line context, we illustrate two studies that have documented the empirical relationship between the size of the market and the progress of pharmaceutical innovation. First, using data from the US, Finkelstein [6] investigated whether an increase in market size resulting from changes in health policies affects R&D investment behavior in the vaccine industry.
2 By comparing changes in the number of new vaccine clinical trials between treatment diseases (affected by the policies) and control diseases (not affected by the policies), Finkelstein found evidence that the expansion of market size induced by changes in health policies has a significantly positive effect on rates of innovation in vaccine markets. The estimates indicate that a US $1 increase in annual expected market revenue from a vaccine leads to a six cent increase in vaccine R&D investment.
Second, Acemoglu and Linn [1] measured changes in market size from demographic trends in the US. During a recent 30-year period, demographic trends led to a decline in the market for drugs consumed mostly by the young (age 0-30). In contrast, markets for drugs consumed mostly by the middle-aged have increased. Acemoglu and Linn [1] found that the change in potential market size, which is measured by a combination of the number of consumers and their incomes, has a significantly positive impact on pharmaceutical innovation: a 1% increase in potential market size leads to an increase in the entry of new drugs of about 4%.
In addition, the rate of technological innovation is influenced by rising incomes and more generous insurance coverage. Hall and Jones [10] developed a conceptual framework to explain why health expenditures command a rising share of national income in many high-income countries. In their framework, they argued that the marginal utility of non-health-care consumption is declining, but that the utility of spending on health is not. As a result, nations spend an increasing share of their income on health care as their national incomes rise. This argument is supported by empirical evidence that the value of life increases twice as fast as income which, in turn, implies that people are willing to pay more for technological innovation as their incomes rise.
As Finkelstein [7] noted, a major expansion in health insurance coverage, such as that which occurred when Medicare was introduced, would lead to market-wide changes. The substantial increases in the demand for care that lead to corresponding increases in revenue are likely to be sufficient to more than offset the fixed cost of entry (e.g., building a new facility, or obtaining regulatory approval for entry). Thus, given the fact that a major demand stimulus occurred, one can expect many providers to enter the market. Furthermore, rates of return on medical research and development are likely to increase, leading to a substantial amount of technological change. This argument is supported by empirical evidence. Finkelstein [7] found that the introduction of the US Medicare program led to substantial new hospital entry and new technology adoption.
In summary, previous research has documented an empirical relationship showing that technological change in medicine is endogenous in the sense that the rate of technological innovation is influenced by various factors inherent in the health care system, such as the size of the market, income and health insurance. Technological innovation, in turn, becomes a major driver of rising healthcare costs. Based on these previous studies, we test the determinants of the technological innovation and their impact on health expenditures empirically in the context of the pharmaceutical market in Taiwan-a country with rapid economic growth and universal health insurance. 3 
Background
Taiwan initiated its National Health Insurance (NHI) program, which covers all citizens, on 1 March 1995. The insurance coverage includes outpatient services, inpatient services and prescription drugs. After implementing the NHI program, the adoption of NHI formula is an important avenue for new prescription drugs to enter into the Taiwanese pharmaceutical market, as most physicians generally prescribe only those drugs that are reimbursed by the NHI program. In the Bureau of NHI-a public agency in charge of administering the NHI program in Taiwan-a pharmaceutical committee comprised of physicians, government officials, and academics determines the NHI formula. After drugs have obtained the approval and licenses for marketing from the Department of Health, most of these prescription drugs will be included in the NHI formula if the single public payer and pharmaceutical manufacturers reach an agreement on the level of the regulated reimbursement prices. So far, around 25,700 drug items have been approved in the NHI formula. In 2011, around 16,700 drug items are still reimbursed by the NHI program. 4 With respect to the reimbursement scheme, the initial reimbursement prices of on-patent branded drugs are based on the median prices of ten developed countries, and the upper limit price of off-patent branded drugs is around 85% of the international median price. 5 Thereafter, the reimbursement prices will be updated based on a 2-year price survey and adjustment. On the demand side, the maximum copayment of pharmaceuticals is currently only NT$ 200, resulting in the brands of drugs for patients being mainly those determined by physicians. 6 Thus, a feature of the Taiwanese pharmaceutical market is that the retail prices of new drugs are regulated by a universal health insurance program [18] . As previous research has focused only on the elderly population by using Medicare data [7] or on results from competitive pharmaceutical and health insurance markets [1] , this paper provides empirical evidence in the context of the pharmaceutical market regulated by a universal health insurance program that covers the entire population.
Empirical framework
To test our hypothesis, an empirical model was constructed using two equations: (1) the entry of new drugs and (2) pharmaceutical expenditure. Equations explaining the determinants of new drugs (NEW) and pharmaceutical expenditure (EXP) are given as follows:
where i denotes the therapeutic category and t indexes the year, X it and Z it are vectors of control variables pertaining to the determinants of the technological innovation and EXP, respectively, and e and l are random error terms. As NEW and EXP are determined simultaneously, NEW and EXP are hypothesized endogenous variables. In order to test the endogeneity of EXP and NEW, the one-period lagged values of EXP and NEW are used as suitable instruments to test the null hypothesis of exogeneity (whereby OLS and IV estimates of the parameters in Eqs. 1 and 2 are asymptotically equivalent) against the alternative hypothesis of endogeneity (wherein the OLS and IV estimates converge to different constants). The Hausman [11] test enables a test of whether the OLS and IV estimates are significantly different from each other, in which case EXP and NEW are endogenous.
In addition, we need to use exclusion restrictions to identify parameters for the simultaneous equations model. The lagged value of EXP is solely in the NEW equation, and the lagged value of NEW is used only in the EXP equation. Thereafter, we use three-stage least squares (3SLS) to estimate the simultaneous relationship between NEW and EXP by using the covariance matrix from the second stage and suitable instruments for the endogenous explanatory variables.
The fixed-effects method and 181 therapeutic dummies are used to control for the unobservable characteristics of the therapeutic groups that may be correlated with the endogenous variables. In addition, the log transformation model is used to estimate Eq. 2 as the distribution of the EXPs tends to be skewed to the right.
Data and variables
The data used in this paper come from two sources. First, we obtained data on NEW included in the formula of the NHI program from the Bureau of NHI. This data set provides information regarding the drug identification number (ID), ingredient name, brand name, dosage, reimbursement price, and the anatomical therapeutic chemical (ATC) code classification system. Second, we obtained data on EXPs and other variables from a longitudinal data set, hereafter referred to as the NHI sampling claims data, that contains 1 million individuals (about 5% of the total population in Taiwan) selected randomly from the registry of NHI beneficiaries in 2005. The sampling file was then merged with insurance claim files that trace back all the medical utilization records of these same individuals in each year and follow their medical utilization data for subsequent years.
The NHI sampling claims data were made publicly available through the National Health Research Institute. This data set contains detailed records on the utilization of personal health-care services, including outpatient visits, hospital admissions and prescription drugs. The data on prescription drugs provide the drug ID, the quantity utilized and total drug expenditures. The advantage of this data set is that all the medical utilization data can be linked together for the same patient. In addition, this data set is based on national sampling data and serves as an adequate representation of the population data. Thus, the summation of drug expenditure across all patients represents the aggregate spending for the same drug in Taiwan.
Between 1996 and 2006, 556 NEW were added to the NHI formula.
7 Table 1 shows the distribution of these NEW across therapeutic groups (defined by the first level of the ATC code). The therapeutic groups that have relatively more pharmaceutical innovation, as measured by the total accumulated numbers of NEW included in the NHI formula during the sample period, include drugs for the central nervous system (N), antineoplastic and immunomodulating agents (L), anti-infectives (J), as well as drugs for the alimentary tract and metabolism (A), and for the cardiovascular system (C). The number of NEW in these five groups accounts for about 62% of all NEW. In contrast, the expenditure on drugs for these five groups accounted for nearly 75% of NHI EXP in 2006. This suggests that therapeutic groups with relatively more pharmaceutical innovation are associated with higher shares of EXP. Alternatively, this also suggests that the therapeutic groups with higher expenditure shares are likely to attract more entries of new products.
In this paper, the observation unit is the therapeutic category, as defined by a four-digit ATC code. 8 As can be seen in the last column of Table 1 , the total number of therapeutic categories in our data set is 182. The sample covers the period from 1997 to 2006, which gives a balanced panel model with 1,820 observations. Table 2 illustrates the definitions and summary statistics of the variables. The first key variable in our empirical analysis is the technological innovation. Following the approach adopted in Lichtenberg [15] , we measure the technological innovation in the pharmaceutical market by the accumulated number of new pharmaceutical products in each therapeutic category, as given by the variable NEW. 9 This variable ranges from 0 to 27 in the data set, with a mean of 1.63, indicating that there is substantial variation in pharmaceutical innovation across therapeutic groups.
The second key variable in our empirical analysis is the size of the market, which is measured by the annual EXP in each therapeutic group. This variable is represented by the variable EXP and expressed in real terms (in 2006 New Taiwan dollars). There is also a substantial variation in annual EXP across therapeutic groups.
Other control variables used in the empirical analysis include the characteristics of the demand side and supply side of the market within each therapeutic group, as well as the major reforms of the payment system in Taiwan. The demand-side variables include mean age of patients who utilize the drugs in each therapeutic categories and the number of patients (PT) that use drugs. The supply-side variables include: (1) the competition in the pharmaceutical market, as measured by the Herfindahl-Hirschman index (HHI) in each therapeutic group; and (2) the size of the buyer, which is measured by the market share (in terms of NHI drug expenditure) of products purchased by larger hospitals, including academic medical centers and metropolitan hospitals (HOSB).
We also add a dummy variable to control the effect of the payment system reform. The variable representing the implementation of the hospital global budget (GB) is set to 0 before 2002, and to 1 thereafter, to measure the impact of the payment system reform for the hospital sector that came into effect in July 2002.
Empirical results
The empirical results are presented in Table 3 . The second and third columns of Table 3 contain the results for the therapeutic fixed effects model, as estimated by OLS, while the fourth and fifth columns in Table 3 shows the results for the therapeutic fixed effects as estimated by IV, that is, by treating EXP and NEW as endogenous variables. The last two columns of Table 3 illustrate the results for the fixed effect model estimated by 3SLS, using 181 dummy variables for the therapeutic categories.
The Hausman test statistics shown at the bottom of Table 3 lead to rejection of the null hypothesis that EXP and NEW are exogenous, in which case they are endogenous. Therefore, the OLS estimates will be biased and inconsistent, and hence lead to biased inferences regarding the simultaneous determination of technological innovation and health expenditure. Based on the fixed effect model estimated by 3SLS, the elasticity of technological innovation with respect to EXP is 1.1481, which is about 46. These results suggest that technological innovation and the growth of health expenditure create an interactive and 7 In the data set, the forms of new prescription drugs include new molecular entities, formulations, combinations, and indications. 8 In the ATC classification system, the 1-, 3-, 4-, and 5-digit codes represent the anatomical main group (1st level), therapeutic subgroup (2nd level), pharmacological subgroup (3rd level), and chemical subgroup (4th level), respectively. 9 A new pharmaceutical product is defined here as one that was included in the NHI formula after 1996.
Endogenous technological change 291 reinforcing cycle. Thus, the effect of technological innovation on the growth of health expenditure will be biased if estimation fails to take into account the interactive nature of technological change in medicine. Thus, we base the following discussion on the simultaneous equations model that accounts for the endogeneity of EXP and NEW using the 3SLS method.
As expected, the coefficients of EXP are positive and statistically significant, indicating that an increase in the size of the market, as measured by the NHI EXP, leads to more rapid progress in technological change in medicine, as measured by the accumulated number of new pharmaceutical products. The estimates indicate that a 10% increase in EXPs leads to an increase of 11.5% in the entry of NEW (elasticity = 1.8714/1.63). Moreover, the entry of new pharmaceutical products significantly increases EXPs. The estimated elasticity reported in the fifth column of Table 3 is about 0.21 (=0.1312 9 1.63), indicating that a 10% increase in the entry of NEW leads to an increase of 2.1% in the EXP. Combining these two effects, the results suggest that technological change in medicine and the growth of health expenditure are determined simultaneously as they are both endogenous variables. On the one hand, an increase in health expenditure implies an expansion in the size of the market which, in turn, provides strong incentives for technological innovation. In other words, as long as new technology is a normal good, the increase in incomes in conjunction with more resources allocated to the health care sector over time will lead to greater utilization of new-technology treatments. Moreover, health insurance coverage of prescription drugs is quite generous in Taiwan, thereby creating an incentive for NEW to be included in the NHI formula.
On the other hand, an increase in the rate of technological innovation introduces more new pharmaceutical products into the health care system, which in turn fuel a rise in health expenditure. Previous research indicates that, because of the higher prices and progress of new technology, the adoption of NEW might increase health expenditures through two channels: treatment substitution and treatment expansion [5] . Liu and Hsieh [17] show that the adoption of new oral hypoglycemic agents, like thiazolidinediones, increases the treatment cost of diabetes patients and the effect of treatment substitution is greater than that of treatment expansion.
With regard to the estimated coefficients of other control variables, the results are, in general, consistent with prior expectations. On the demand side, we find that the estimated coefficients for the number and average age of patients (PT and AGE) and are positive and statistically significant in the EXP equation, indicating that therapeutic groups in which the products are used by more elderly patients are more likely to have higher costs. On the supply side, we find that the degree of market concentration is associated negatively with the entry of new products. This result suggests that a highly competitive market is likely to attract the entry of more new products.
We also find that the buyer size within the therapeutic group has a significantly positive impact on both the entry of new products and EXPs. This result indicates that therapeutic markets with more big buyers, as measured by the higher market share of larger hospitals, are more likely to attract new products to enter the market which, in turn, also have a more significant impact on the growth of EXPs. This finding, in combination with the previous results, suggests that not only market size, but also the distribution of market size toward larger buyers, have significant impacts on the entry of new products. A plausible explanation for this result is that larger buyers may help the supplier to save on marketing costs, and hence increase their expected returns. Thus, pharmaceutical firms are more likely to develop new products where their markets are concentrated toward larger hospitals.
The coefficients of GB are significantly positive in the equation of EXP, indicating that the implementation of global budgets might increase the market size of pharmaceutical markets. This might stem from the nature of policy design in that the pharmaceutical expenditure is subtracted from the overall budget before the reimbursement price of non-drug services is determined, and the reimbursement price of drugs is based on the public regulated price, which is known prior to the delivery of the health care service. That is, under the current rule of global budgeting in Taiwan, the reimbursement price for non-drug service is variable, but the reimbursement price for drug treatment is fixed. Thus, in order to avoid the uncertainty in hospital revenues generated from non-drug services, hospitals tend to spend more on drugs.
Finally, we find that the estimated coefficient of the variable measuring the time trend is positive and significant in the NEW equation, indicating that the entry of NEW increases over time.
Conclusion
This paper uses a simultaneous equations approach to investigate empirically the interactions between technological innovation and the growth in health expenditures.
Using the pharmaceutical market in Taiwan for the period 1997-2006, this paper presents several important findings. First, we find that therapeutic groups associated with higher EXPs are more likely to attract the entry of more new products. The estimated elasticity, which measures the responsiveness of technological innovation with respect to health expenditure, is [1, suggesting that the technological innovation is influenced strongly by market size.
Second, the results also confirm the previous finding of Okunade and Murthy [21] that technological innovation is an important driver of rising health care costs. The results show that the estimated elasticity, which measures the responsiveness of health expenditure with respect to technological innovation, is 0.21.
Third, the Hausman test statistics indicate that technological innovation in medicine is endogenous in the simultaneous relationship with health expenditures. In addition, the estimated elasticity derived from the fixed effect model estimated by 3SLS differs significantly from that derived from the same model estimated by singleequation IV. This finding suggests that the effect of technological innovation on the growth of health expenditure will be biased statistically if we fail to take into account the simultaneity problem between technological innovation and health expenditure.
The empirical results of the paper have three important policy implications. First, technological changes in medicine and health expenditure are determined simultaneously in the sense that they work together and reinforce each other. Thus, the cost containment policy adopted in the health sector becomes a double-edged sword: it reduces not only the growth rate of health expenditure, but also the rate of technological innovation. Given that technological change in medicine is an important contributor to improvements in population health, the simultaneous determination of technological innovation and health expenditure will result in governments facing more severe policy dilemmas in trying to control health care costs while also improving the population's health.
Second, given that it funds the major portion of health care expenditure in many countries, the public sector often chooses ''new technology'' as the target of a cost containment policy. As technological innovation is endogenous in the sense that many factors beyond the control of the public sector provide fuel to induce the progress of new technology (e.g., market size and income), the cost containment effort may not control the growth in health expenditure effectively. Rather, such a policy simply shifts the financing of new technology from the public to the private sector. An increase in the private financing of new technology may become an access barrier to new technology among low-income populations. For the supply side, the cost containment policy may also decrease the rate of return for new-drug investment, thereby reducing incentives for pharmaceutical innovation.
Third, improving health status, rather than containing health care costs, is the main goal of health care policy. If the utilization of high-technology treatment improves health outcomes of the overall population, eventually the value of adopting high-technology treatment might outweigh the increase in healthcare costs. Lichtenberg [16] shows that a higher quality of health care increases life expectancy, though it does increase health expenditure per capita. Therefore, creating a virtuous cycle between technological innovation and health expenditure by adopting new technology based on cost-effectiveness evidence provides one avenue for policy makers to shape their health care policy.
One limitation of this paper is that we focus only on pharmaceutical innovations. Other forms of technological change in medicine, such as progress in diagnostic technologies, also account for a large part of the growth in health care expenditure. Future research may use diagnostic technologies to investigate the interactive relationship between technological innovation and the growth in health expenditure.
